SCHEMBL7199713

SCHEMBL7199713

Oc1ccc2c(c1I)OCCO2

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.44
ITGB2 P05107 1/20 0.36
ICAM1 P05362 1/20 0.36
ITGAL P20701 1/20 0.36
DRD2 P14416 2/20 0.35
DRD1 P21728 2/20 0.35
HTR2A P28223 2/20 0.35
DRD3 P35462 2/20 0.35
KDM4E B2RXH2 2/20 0.35
DRD4 P21917 1/20 0.35
SIGMAR1 Q99720 1/20 0.35
AOC3 Q16853 1/20 0.35
HTT P42858 2/20 0.35
ERN1 O75460 1/20 0.35
ALDH1A1 P00352 1/20 0.35
HPGD P15428 1/20 0.35
HSD17B10 Q99714 1/20 0.35
POLB P06746 1/20 0.34
MRGPRX1 Q96LB2 1/20 0.33
P4HB P07237 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12023077 0.78 ALOX5 (0.47) ALOX5ITGB2ICAM1ITGALDRD2
SCHEMBL25352397 0.75 ALOX5 (0.44) ALOX5ITGB2ICAM1ITGALDRD2
SCHEMBL26005665 0.75 ALOX5 (0.44) ALOX5ITGB2ICAM1ITGALDRD2
SCHEMBL30438835 0.75 ALOX5 (0.44) ALOX5ITGB2ICAM1ITGALDRD2
SCHEMBL12023063 0.72 AOC3 (0.47) ALOX5KDM4EAOC3ALDH1A1POLB
SCHEMBL7201013 0.72 KDM4E (0.44) ALOX5DRD2DRD1HTR2ADRD3
SCHEMBL3077219 0.71 DRD2 (0.53) ALOX5ITGB2ICAM1ITGALDRD2
SCHEMBL29664384 0.71 KDM4E (0.45) ALOX5KDM4EAOC3HTTERN1
SCHEMBL1494021 0.71 ALOX5 (0.41) ALOX5ITGB2ICAM1ITGALDRD2
SCHEMBL27253938 0.71 KDM4E (0.45) ALOX5KDM4EAOC3HTTERN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6602903-B2 Substituted O- and/or S heterocyclic compounds; powerful ligands for melatoninergic receptors. LES LABORATORIES SERVIER (FR) 2003-08-05 US disclosed
US-20020052400-A1 Substituted heterocyclic compounds ADIR ET COMPAGNIE 2002-05-02 US disclosed
US-6313160-B1 FOR THERAPY AND PROPHYLAXIS OF MELATONINERGIC DISORDERS ADIR ET COMPAGNIE (FR) 2001-11-06 US disclosed
EP-0998471-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS, METHOD FOR PREPARING AND COMPOSITIONS CONTAINING SAME ADIR ET COMPAGNIE (FR) 2000-05-10 EP disclosed
WO-1998052935-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS, METHOD FOR PREPARING AND COMPOSITIONS CONTAINING SAME ADIR ET COMPAGNIE (FR) 1998-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020052400-A1 Substituted heterocyclic compounds MTNR1A, MTNR1B, CBR1 ALOX5 567/4885ITGB2 3876/4885ICAM1 4109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.